Drug Profile

Fuzuloparib - Jiangsu HengRui Medicine

Alternative Names: Fluzoparib; HS-10160; SHR 3162

Latest Information Update: 16 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Developer Chinese PLA General Hospital; Jiangsu Hengrui Medicine Co.; Tianjin Medical University Cancer Institute and Hospital
Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Phthalazines; Pyrazines; Small molecules; Triazoles
Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Solid tumours

Marketed Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
Phase III HER2 negative breast cancer; Pancreatic cancer
Phase II Glioblastoma
Phase I/II Small cell lung cancer
No development reported Gastric cancer; Solid tumours; Triple negative breast cancer

16 Dec 2025 Launched for Breast cancer in China (PO) before December 2025 (Jiangsu Hengrui Medicine pipeline, December 2025)
16 Dec 2025 Launched for Prostate cancer (Hormone refractory, Metastatic disease) in China (PO) before December 2025 (Jiangsu Hengrui Medicine pipeline, December 2025)
16 Dec 2025 Registered for Breast cancer in China (PO) before December 2025 (Jiangsu Hengrui Medicine pipeline, December 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com